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to be a primary epigenetic modification pattern in humans (Jones 
and Takai, 2001) and a critical mechanism for regulating gene 
expression and facilitating adaptation to environmental stres-
sors (Abdolmaleky et al., 2004). Changes in methylation patterns 
play an important role in various human diseases, such as cancer 
(Feinberg and Tycko, 2004) and psychiatric disorders (Murphy 
et al., 2005; Abdolmaleky et al., 2006). On the other hand, there 
have been only a few studies of methylation in humans involved in 
substance abuse (Bonsch et al., 2004, 2005; Philibert et al., 2008a,b; 
Biermann et al., 2009; Hillemacher et al., 2009; Nielsen et al., 2009). 
For example, Philibert et al. (2008a) found that the methylation 
status of the promoter region of monoamine oxidase A (MAOA) 
was significantly associated with lifetime symptom counts for 
ND and alcoholism in women, a conclusion they reached after 
performing quantitative methylation analysis of DNA extracted 
from lymphoblasts derived from 191 subjects participating in the 
Iowa Adoption Studies (IAS). In another study with this sample, 
the same research group found that CpG methylation of the sero-
tonin transporter gene was higher in female than male subjects 
(Philibert et al., 2008b). By direct sequencing of bisulfite-treated 
DNA obtained from lymphocytes of 194 former heroin addicts 
stabilized on methadone maintenance and of 134 control sub-
jects, Nielsen et al. (2009) found that the percent methylation 
at two of 16 CpG sites in the promoter region of OPM1 was sig-
nificantly associated with heroin addition. Because both of the 
IntroductIon
Tobacco use is the leading cause of preventable death throughout 
the world. In the United States alone, smoking causes approximately 
438,000 premature deaths and $167 billion in health-related costs 
annually (Mokdad et al., 2004). Numerous earlier studies demon-
strated that nicotine is the primary addictive substance in tobacco 
smoke, stimulating the release of dopamine from neurons in the 
ventral tegmental area (Stolerman and Jarvis, 1995; USDHHS, 
2000; WHO, 2002). Furthermore, twin and family studies reveal 
that nicotine dependence (ND) is a complex disorder determined 
by both genetic and environmental factors, as well as interactions 
between genes or between genes and the environment (Carmelli 
et al., 1992; Heath et al., 1999; Kendler et al., 2000; Li, 2003; Li 
et al., 2003; Swan et al., 2003; Swan and Lessov, 2004). Although 
numerous studies have shown that genetic variants contribute to 
the etiology of ND (Li, 2008; Li and Burmeister, 2009), the com-
plex interplay between genetic and environmental factors is largely 
unknown.
It has become increasingly clear that environmental factors 
can influence epigenetic mechanisms such as DNA methylation, 
histone modification, and chromatin restructuring, leading to 
changes in gene expression (Tsankova et al., 2007). Such changes 
can be especially problematic in individuals with genetic suscepti-
bilities to specific diseases (Abdolmaleky et al., 2004). Methylation 
of CpG islands in the promoter region of a gene has been   suggested 
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20 cigarettes per day for the last 12 months. Non-smoker con-
trols were subject to the following additional selection criteria: 
(1) smoked no more than 100 cigarettes in their lifetimes; (2) 
engaged in no regular use of any other tobacco products (e.g., 
cigars, smokeless tobacco) or nicotine replacement products (e.g., 
nicotine gum, nicotine patches); (3) had not used any tobacco 
or nicotine replacement products in the last year; and (4) had an 
expired alveolar CO < 8.0 ppm.
In the current study, 150 smokers and 150 non-smoker controls 
of African-American origin were selected, with an equal number 
of men and women in each group. The average age was 45.5 ± 5.86 
(SD) years for the smoker group and 44.6 ± 6.59 years for the non-
smoker control group. The average number of cigarettes smoked 
per day, Heaviness of Smoking Index (HSI), and Fagerstro ˝m Test for 
ND (FTND) (Heatherton et al., 1991) of smokers were 24.6 ± 14.7, 
4.64 ± 1.4, and 7.47 ± 3.15, respectively.
PreParatIon of genomIc dna and bIsulfIte modIfIcatIon
Genomic DNA was isolated from whole blood samples of each 
participant using the DNA Maxi kit from Qiagen, Inc. (Valencia, 
CA, USA) according to the manufacturer’s protocol. About 500 ng 
of DNA was treated with sodium bisulfite using the EpiTect Bisulfite 
Kit (Qiagen GmbH, Hilden, Germany) according to the manufac-
turer’s protocol. The bisulfite-treated DNA was eluted in 30 μl of 
EB buffer.
bIsulfIte sequencIng and methylatIon analysIs
Primers for amplifying the CpG islands in the promoter region 
of  MB-COMT  from  bisulfite-treated  DNA  were  designed 
with Methyl Primer Express version 1.0 (Applied Biosystems, 
Foster City, CA, USA). Amplification was performed with 1 μl 
of  bisulfite-treated  DNA;  0.4  μM  of  each  primer  (primer  A: 
5′-TGGGATATTAGTTTTGGGAGAT-3′ and primer B: 5′-TCCC
AATATTCCACCCTAAATCTA-3′); 0.2 mM each of dATP, dCTP, 
dGTP, and dTTP; 1.5 mM MgCl2; and 1.0 unit of Platinum Taq 
DNA Polymerase (Invitrogen) in a total volume of 25 μl. The 
amplification conditions consisted of 4 min at 95°C; 5 cycles of 
30 s at 95°C, 90 s at 56°C, and 120 s at 72°C; then 25 cycles of 
30 s at 95°C, 90 s at 56°C, and 90 s at 72°C; followed by a final 
elongation step at 72°C for 4 min. A second round of ampli-
fication was performed using 2 μl of the first amplified prod-
uct with primer A and the nested primer C with the sequence 
5′-AACAACCCTAACTACCCCAAAA-3′).  The  amplification 
conditions for the second round consisted of 4 min at 95°C; 5 
cycles of 30 s at 95°C, 90 s at 52°C, and 120 s at 72°C; then 25 
cycles of 30 s at 95°C, 90 s at 52°C, and 90 s at 72°C; followed by a 
final elongation step at 72°C for 4 min. After the second round of 
amplification, the DNA fragments were recovered and sequenced 
using the ABI 3730 XL sequencer.
Quantitative methylation rates were estimated from sequence 
trace files using ESME software (v. 3.2.1) from Epigenomics AG 
(Berlin, Germany), which involved appropriate quality control, 
normalization of signals, correction for incomplete bisulfite con-
vention, and mapping of positions in the trace file to CpGs in 
reference sequences as described by Lewin et al. (2004). The ESME 
software was run on a virtual machine (VMware player on Windows 
XP) running Red Hat Enterprise Linux 4.
sites are located in potential Sp1 transcriptional factor-binding 
sites, it has been hypothesized that methylation of these CpG sites 
leads to reduced OPM1 expression in the lymphocytes of these 
former heroin addicts. Considering the role that dopaminergic 
neurotransmission plays in the genesis and maintenance of drug 
dependence, Hillemacher et al. (2009) examined promoter specific 
methylation of the dopamine transporter (DAT) gene and found 
that subjects with alcohol dependent showed significant hyper-
methylation in the DAT promoter.
Previously, we reported that the genetic variants of catechol-
O-methyltransferase  (COMT)  were  significantly  associated 
with ND in smokers (Beuten et al., 2006). Further, two recent 
investigations revealed a strong association between the COMT 
Val108/158Met genotype and smoking cessation or other smoking 
behaviors (Colilla et al., 2005; Johnstone et al., 2007). The enzyme 
encoded by this gene catalyzes the transfer of a methyl group 
from S-adenosyl-methionine to the hydroxyl group of catecho-
lamines, including the neurotransmitters dopamine, epinephrine, 
and norepinephrine, or of the catechol estrogen (Weinshilboum 
et al., 1999). Also, COMT plays a critical role in the degrada-
tion and inactivation of extraneuronal dopamine and may be 
involved in a variety of mental disorders (Akil et al., 2003; Chen 
et al., 2004).
The COMT has two promoters, P1 and P2, which control tran-
scription  of  different  mRNAs.  The  membrane-bound  COMT 
(MB-COMT), encoded in mRNA transcribed from the P2 pro-
moter, is expressed predominantly in brain neurons (Tenhunen 
et al., 1994). Hypermethylation of CpG islands in the promoter of 
MB-COMT correlates with hypoexpression of COMT in endome-
trial cancer (Sasaki et al., 2003), and a recent independent study 
showed this methylation to be a significant risk factor for schizo-
phrenia and bipolar disorder (Abdolmaleky et al., 2006). Together, 
these findings imply that MB-COMT is a good candidate for the 
study of DNA methylation in determining vulnerability to ND. 
The present study was performed to determine differences in the 
methylation of the MB-COMT promoter in patients with ND 
and age- and sex-matched non-smokers by detecting methylation 
of cytosines at 33 CpG sites in the promoter region of the gene 
through sodium bisulfite modification using DNA sequencing and 
methylation-specific PCR.
materIals and methods
study PartIcIPants
All participants were selected from the database developed for 
a large family-based genetic study of ND, called the Mid-South 
Tobacco Family (MSTF) study, in which every participant pro-
vided informed consent. The study protocol and all other related 
forms/procedures were approved by all participating Institutional 
Review Boards. A detailed description of the MSTF study is pro-
vided in previous publications from this group (Li et al., 2006, 
2007, 2008). Briefly, we requested each participant to have no (1) 
history of using abused substances other than nicotine and alco-
hol over the past 12 months; (2) a history of any serious mental 
disorder; or (3) a blood/genetic relationship between smokers and 
non-smoker controls. Additional selection criteria for smokers 
were that they had to be at least 18 years of age, to have smoked 
for at least the last 5 years, and to have consumed an average of www.frontiersin.org  June 2010  | Volume 1  | Article 16  |  3
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statIstIcal analysIs
Statistical  analysis  and  plotting  of  data  were  performed  with 
GraphPad Prism (GraphPad Software Inc., San Diego, CA, USA). 
The MB-COMT methylation is given as percentage of methylation 
of each CpG site. A significant level of α = 0.05 or less was con-
sidered significant. Comparisons were made using Student’s t-test 
on Systat software (Systat Software Inc., Chicago, IL, USA), and 
all tests were two-tailed. To meet the assumption of normality, we 
did a logarithmic transformation to the base e for the percentage 
of methylation at each CpG site.
results
methylatIon status of 33 cpg sItes In the Promoter regIon of 
MB-COMT
Using the program provided on the website www.urogene.org/
methprimer, we predicted a CpG island in the promoter region of 
MB-COMT (i.e., within about 560 nucleotides from the transcrip-
tion start site) under the definition island size >100, GC% >50.0%, 
and Obs/Exp >0.6 (Gardiner-Garden and Frommer, 1987). Figure 1 
shows the sequence of the MB-COMT promoter from nucleotides 
−256 to +51 relative to the transcription start site. This DNA frag-
ment contains potential binding motifs for transcription factors 
AP-2, Sp1, Ets-1, and NF-D (Tenhunen et al., 1994). In the current 
study, 33 CpG dinucleotides were investigated; they are located at 
nucleotides −211, −195, −193, −179, −161, −158, −156, −154, −142, 
−131, −127, −125, −123, −112, −110, −104, −99, −79, −74, −72, −69, 
−67, −62, −55, −51, −46, −39, −35, −29, −23, −8, −3, and +4.
By direct bisulfite sequencing of the PCR product from sodium 
bisulfate-modified genomic DNA, we examined the methylation 
states of all 33 CpG sites in 50 smokers and 50 non-smoker con-
trols. We found that 13 cytosines of the 33 CpG dinucleotides were 
methylated in at least some of the samples. This pattern was read 
as “N” by the sequence reader or showed “C” and “T” peaks to 
different degrees.
dIfferentIal methylatIon at the −193 and −39 cpg sItes In 
smokers and non-smoker controls
On the basis of direct bisulfite sequencing results from 48 smoker 
and 45 non-smoker control samples from which we have gener-
ated reliable sequence information with certainty, we found no 
methylatIon-sPecIfIc Pcr
After sodium bisulfite conversion, genomic DNA was amplified with 
primers A and C using the procedure described above for the first 
round of amplification, except that 15 instead of 25 cycles were 
used. The amplification products were detected with fluorescence-
based, real-time quantitative PCR according to the manual of the 
TaqMan® Gene Expression Assay (Applied Biosystems). Briefly, 
real-time PCR was performed in a 96-well optical microplate in a 
final volume of 20 μl consisting of 10 μl of TaqMan® Universal PCR 
Master Mix, No AmpErase® UNG (uracil-N-glycosylase), 2 μl of 
amplified products, an additional 2.5 U of AmpliTaq Gold (Perkin 
Elmer), 2.5 μM each of the primers 193Fwd and 193Rev, and 150 nM 
each of the fluorescently labeled probes 193Met and 193Unmet (the 
sequences of these primers are given below). Serial dilutions of a 
control sample were included in each plate to generate a standard 
curve. Initial denaturation at 95°C for 10 min was followed by 40 
cycles of denaturation at 95°C for 15 s and annealing and extension 
at 60°C for 1 min (ABI Prism, 7500 Sequence Detection System). 
All samples were measured in duplicate, and an average of the two 
duplicates was used for statistical analysis. The methylation percent-
age of each sample was compared with a standard curve according 
to the approach described by Zeschnigk et al. (2004).
To generate a standard curve, different ratios of methylated and 
unmethylated target sequences were prepared. The unmethylated 
sequence was produced using an amplified DNA fragment ensured 
to be unmethylated by bisulfite sequencing; it was cloned using the 
TA Cloning Kit (Invitrogen), yielding the PCR193UM plasmid. For 
the methylated target sequence, plasmid PCR193M was generated 
from the PCR193UM plasmid with the target nucleotide “T” being 
changed to “C” using a site-directed mutagenesis kit purchased 
from Stratagene Inc. (La Jolla, CA, USA). The following methylated/
unmethylated ratios were prepared by mixing appropriate target 
sequences: 0/100, 20/80, 40/60, 60/40, 80/20, and 100/0.
The TaqMan® probes and primers were designed to amplify 
the target CpG site detected by bisulfite sequencing. The primer 
sequences are: 193Fwd: 5′-AGATTAGATTAAGAGGTTGGTATGTG
GAT-3′ and 193Rev: 5′- CAACAATAACCAAAATATCCCCATAA-3′. 
The probe sequences are: 193Met: 5′-VIC-TTTTGCGTGGGTATTT-
MGB-3′  and  193Unmet:  5′-6FAM-  CCACACAAAAATATCC-
MGB-3′.
-256
TGGGATACCAGCTCTGGGAGACCACAGGTGCAGTCAGCACAGCAGGACCTTAGACAAGGCACCCAGCCCCAGTTTCCCCACCTGGGAAGGG
GGCTACTTGTGGCTAGAAGCAGCC-243CGGACTCCTGAGCAAGACTAGACCAAGAGGC-211CGGTATGTGGACACCCC-195CG-193CGTGGG
CACCCCCA-179CGGGGACACCCTGGCCAC-161CGC-158CG-156CG-154CGGACACCCTCA-142CGAGGACACCC-131CGGC-127CG-125CG
-123CGGACACCTAC-112CG-110CGGGGA-104CGCCC-99CGACCCCATCCTACCTGCTG-79CGCCC-74CG-72CGC-69CG-67CGCCC-62CGCACC
+1
C-55CGCC-51CGCCA-46CGGCCTG-39CGTC-35CGCCAC-29CGGAAG-23CGCCCTCCTAATCCC-8CGCAG-3CGCCAC+4CGCCATTGC+13CGCC
+51
AT+19CGT+22CGTGGGGCTTCTGGGGCAGCTAGGGCTGCC
FiGure 1 | Sequence of the MB-COMT promoter. This DNA fragment is 
located from nucleotides −256 to +51, and the cytosine shown in bold 
marked +1 is the 5′ end of the encoded mRNA. The underlined sequences 
mark the location of the nested PCR primers for bisulfite sequencing. The 
cytosines at 33 CpG sites are numbered −243 ∼ +22 with CpGs shown 
in bold.Frontiers in Psychiatry  |  Molecular Psychiatry    June 2010  | Volume 1  | Article 16  |  4
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knowledge, no studies have investigated the methylation status of 
MB-COMT in smoking-related phenotypes. Thus, our findings 
provide the first molecular explanation at the epigenetic level for 
a direct relation between the risk of ND and methylation altera-
tions of MB-COMT.
Previously, on the basis of a family-based genetic association 
study, we found that allelic variants of COMT are significantly 
associated with ND (Beuten et al., 2006); and in the present study, 
hypermethylation at two CpG sites in the promoter region of 
COMT was found in smokers compared with age- and sex-matched 
non-smokers, suggesting both genetic and epigenetic processes play 
a role in the association of COMT with ND. Given that several 
  significant difference in the mean methylation of all the 13 methyl-
ated CpG sites between the two groups. However, two sites showed 
significantly different methylation extents between the smoker and 
non-smoker samples (Figure 2). At the −193 CpG site, the level of 
methylation was 19.1% in smokers and 13.2% in non-smokers 
(P < 0.01). And at the −39 CpG site, the level of methylation was 
9.2% in smokers, whereas no methylation was found in non-
smoker controls.
To validate the significance of these methylation differences, 
we examined an additional 100 DNA samples plus the original 50 
samples used for bisulfite sequencing employing real-time methyl-
ation-specific PCR. Compared with the standard curve, the average 
extent of methylation at the −193 CpG site was 22.2% (ranging 
from 12.1% to 39.4%) for the smoker group and 18.3% (ranging 
from 11.1% to 31.1%) for the non-smoker control group. When 
the methylation ratios were logarithmic-transformed to the base 
e, the smokers showed a significantly higher methylation rate than 
controls (P < 0.01; Figure 3). As for the −39 CpG site, although we 
examined different TaqMan® probes and primers designed spe-
cifically for this site, we found no probes or primers that worked 
effectively. Therefore, real-time methylation-specific PCR could 
not be performed.
dIscussIon
In this study, we investigated the methylation patterns of cytosines 
at 33 CpG islands in the promoter region of MB-COMT using 
bisulfite  sequencing.  Although  no  significant  difference  was 
detected between smokers and non-smoker controls in the mean 
methylation level of all the sites, a significantly higher extent of 
methylation was found in smokers at the −193 and −39 CpG sites. 
Moreover, the hypermethylation at −193 was confirmed by another 
methylation detection approach and in more DNA samples. To our 
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FiGure 2 | Percent methylation of 13 CpG sites by bisulfite sequencing in the promoter region of MB-COMT in smoker and non-smoker control samples. 
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FiGure 3 | Percent methylation of the −193 CpG site by methylation-
specific PCr in MB-COMT promoter in smoker and non-smoker control 
samples. To meet the assumption of normality, methylation rates were 
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significant methylation rate was verified with methylation-specific 
PCR only at −193 site, thus the significant methylation status at 
−39 site remains to be further verified in the future with other 
techniques in the same or different samples.
There are two limitations of the present study. First, the DNA 
was extracted from the lymphocytes of peripheral blood, and it 
is possible that the methylation status does not represent exactly 
what happens in the brain, a key organ for the development of ND. 
Although we acknowledge it is important to investigate methyla-
tion status in DNA extracted from brain tissue, this does not imply 
that investigation of the methylation status in lymphocytes is less 
important. This is because: (1) the blood cells, which are more 
readily obtained, have been valuable biological resources for many 
genetic studies at various molecular levels, including methylation 
status; and (2) genome-wide expression profiling studies reveal a 
high similarity of expression pattern in the cells of the brain and 
the peripheral blood (Gladkevich et al., 2004). Nevertheless, this is 
an issue faced by almost all brain researchers, as brain tissue is not 
readily available from human research subjects. Thus, whether our 
detected methylation signatures of COMT gene in the blood can be 
replicated in the brain remains to be verified in postmortem tissue. 
Second, we were not able to determine whether these methylation 
changes lead to different expression of genes between smokers and 
non-smokers. To answer this question would require a new study 
in which we can collect both DNA and RNA simultaneously from 
each subject. Unfortunately, we do not have RNA extracted from 
the blood of these subjects as we did for DNA sample, because the 
samples were collected several years ago and processed for our 
genetic studies on ND. Although this is indeed an essential question, 
it is beyond of scope of the current study. A new study designed 
specifically to test this hypothesis is needed in the future.
In summary, we identified two hypermethylation sites in the 
promoter region of MB-COMT in smokers compared with non-
smoker controls. This indicates that methylation in the promoter 
region of the gene contributes at least partly to our previously 
observed association of COMT with ND. Given that DNA meth-
ylation is an important factor in regulating gene expression, we 
hypothesize that increased methylation in the promoter region of 
MB-COMT in smokers would lead to low level of expression of 
the genes in smokers compared to non-smokers. Unfortunately, we 
could not test this hypothesis, as we have no RNA samples available 
from these subjects. Thus, a study designed specifically to test this 
hypothesis is warranted.
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potential binding motifs for transcription factors are contained 
in the flanking sequence of the two CpG sites in the MB-COMT 
promoter, the hypermethylation of the two specific CpG sites may 
be associated with a change in expression of this gene, generally 
reducing its expression (Ngo et al., 1996). This implies that in our 
samples, low expression of MB-COMT correlates with a higher 
risk of ND, which is consistent with the results of our previous 
genetic association study, where we found that low enzyme activity 
correlated with higher vulnerability to ND (Beuten et al., 2006). 
Therefore, individuals with low expression of COMT may experi-
ence longer-lasting and more abundant dopamine release in the 
brain, increasing the magnitude or duration of the reward derived 
from cigarette smoking and the risk of becoming nicotine depend-
ent. Furthermore, the reward processes of neurotransmitters are 
mediated primarily by dopaminergic pathways (Kalivas, 1993). 
Recently, significant hypermethylation of the DAT promoter was 
found in patients with alcohol dependence compared with healthy 
controls, suggesting that hypermethylation of the DAT promoter 
may play an important role in dopaminergic neurotransmission 
and is associated with decreased alcohol craving (Hillemacher 
et al., 2009).
In the current study, two methods (i.e., direct bisulfite sequencing 
and methylation-specific PCR) were used to detect the methylation 
of MB-COMT. Although our bioinformatical analysis predicted 
that CpG islands exist in the promoter region of the gene, it cannot 
predict which one is indeed methylated. Direct bisulfite sequencing 
can be used for detailed analysis of DNA methylation and inform 
us of the status of methylation of every CpG site, but the use of this 
method is commonly limited by the number of samples that can 
be assayed, as many labor-intensive steps are involved in the proc-
ess. On the other hand, methylation-specific PCR is more specific, 
sensitive, and only need small amounts of template DNA and allows 
rapid analysis of large samples. However, the primers and probes 
have to be designed specifically on the basis of the status of methyla-
tion known from genomic sequencing, which can be challenging in 
some cases (Eads et al., 2000; Zeschnigk et al., 2004). For example, 
in the current study, we could not perform the methylation-spe-
cific PCR specifically for the −39 CpG site although we had tested 
various combinations of different TaqMan® probes and primers 
designed specifically for the site. Compared with the aforemen-
tioned two approaches, the pyrosequencing technique has some 
advantageous, as it combines the capability for direct quantitative 
sequencing with reproducibility, speed, and ease of use (Dupont 
et al., 2004). However, the pyrosequencing has its own limitation as 
well such as it can only read the length of approximately 150 bases 
(Tost and Gut, 2007), which makes it less suitable for an investi-
gation where a large DNA fragment is requested to be examined 
such as the case reported here. Based on these comparisons, we 
adopted direct bisulfite sequencing and methylation-specific PCR 
in this investigation. Through direct genome sequencing analysis 
of a small number of samples, we detected the methylation status 
of all CpG sites and identified two sites (i.e., −193 and −39) that 
appeared to be significantly different between smokers and non-
smoker controls. Following identification of these two CpG sites, 
we analyzed more samples using methylation-specific PCR with the 
goal of confirming our direct sequencing finding. Unfortunately, Frontiers in Psychiatry  |  Molecular Psychiatry    June 2010  | Volume 1  | Article 16  |  6
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